Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Cash & Equivalents (2016 - 2025)

Purple Biotech has reported Cash & Equivalents over the past 7 years, most recently at $15.0 million for Q4 2022.

  • Quarterly Cash & Equivalents rose 38.02% to $15.0 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $15.0 million through Dec 2022, up 38.02% year-over-year, with the annual reading at $15.0 million for FY2022, 33.64% up from the prior year.
  • Cash & Equivalents was $15.0 million for Q4 2022 at Purple Biotech, up from $10.9 million in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $23.5 million in Q1 2022 and troughed at $2.8 million in Q2 2019.
  • The 5-year median for Cash & Equivalents is $10.7 million (2021), against an average of $9.7 million.
  • Year-over-year, Cash & Equivalents crashed 41.6% in 2018 and then skyrocketed 156.49% in 2020.
  • A 5-year view of Cash & Equivalents shows it stood at $5.2 million in 2018, then fell by 15.07% to $4.4 million in 2019, then skyrocketed by 156.49% to $11.2 million in 2020, then decreased by 3.17% to $10.9 million in 2021, then skyrocketed by 38.02% to $15.0 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Cash & Equivalents are $15.0 million (Q4 2022), $10.9 million (Q3 2022), and $10.9 million (Q2 2022).